# Mineralys Therapeutics, Inc. (MLYS) ROE: -23.9% in 2025

URL: https://funkfolio.com/stock/MLYS/roe

> Mineralys Therapeutics, Inc. (MLYS) return on equity (ROE) was -23.9% in fiscal 2025, up 69.1 points from fiscal 2024. Year-by-year chart and table.

---

## Mineralys Therapeutics, Inc. (MLYS) return on equity (ROE)

**Return on equity · fiscal 2025:** -23.9% year ended Dec 31, 2025

Mineralys Therapeutics, Inc. (MLYS) earned a return on equity of -23.9% in fiscal 2025 (the year ended December 31, 2025). That is 69.1 percentage points higher than the -93.0% of fiscal 2024. Figures as of 17 Nov 2026, 23:18 UTC, from Yahoo Finance.

### Key facts

- **Return on equity, fiscal 2025:** -23.9%
- **Change on fiscal 2024:** +69.1 pts
- **Highest on record:** -23.9% fiscal 2025
- **Lowest on record:** -93.0% fiscal 2024
- **Fiscal years on record:** 3 2023–2025

Figures as of 17 Nov 2026, 23:18 UTC. Statements from Yahoo Finance. Figures, not advice.

### Mineralys Therapeutics, Inc. return on equity (ROE), in more detail

Across the 3 fiscal years on record (2023–2025), the highest was -23.9% in fiscal 2025 and the lowest -93.0% in fiscal 2024.

### Return on equity by fiscal year

### Mineralys Therapeutics, Inc. return on equity (ROE), year by year

Mineralys Therapeutics, Inc. (MLYS) return on equity (ROE) by fiscal year

| Fiscal year | Return on equity | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | -23.9% | 69.1 pts up | Dec 31, 2025 |
| 2024 | -93.0% | 63.2 pts down | Dec 31, 2024 |
| 2023 | -29.8% | — | Dec 31, 2023 |

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

### How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

### Mineralys Therapeutics, Inc., figure by figure

- [Mineralys Therapeutics, Inc. market cap](https://funkfolio.com/stock/MLYS/market-cap)
- [Mineralys Therapeutics, Inc. revenue](https://funkfolio.com/stock/MLYS/revenue)
- [Mineralys Therapeutics, Inc. earnings](https://funkfolio.com/stock/MLYS/earnings)
- [Mineralys Therapeutics, Inc. earnings per share (EPS)](https://funkfolio.com/stock/MLYS/eps)
- [Mineralys Therapeutics, Inc. P/E ratio](https://funkfolio.com/stock/MLYS/pe-ratio)
- [Mineralys Therapeutics, Inc. P/S ratio](https://funkfolio.com/stock/MLYS/ps-ratio)
- [Mineralys Therapeutics, Inc. P/B ratio](https://funkfolio.com/stock/MLYS/pb-ratio)
- [Mineralys Therapeutics, Inc. free cash flow](https://funkfolio.com/stock/MLYS/free-cash-flow)
- [Mineralys Therapeutics, Inc. operating margin](https://funkfolio.com/stock/MLYS/operating-margin)
- [Mineralys Therapeutics, Inc. dividend](https://funkfolio.com/stock/MLYS/dividend)
- [Mineralys Therapeutics, Inc. shares outstanding](https://funkfolio.com/stock/MLYS/shares-outstanding)
- [Mineralys Therapeutics, Inc. total debt](https://funkfolio.com/stock/MLYS/total-debt)
- [Mineralys Therapeutics, Inc. cash on hand](https://funkfolio.com/stock/MLYS/cash)
- [Mineralys Therapeutics, Inc. total assets](https://funkfolio.com/stock/MLYS/total-assets)
- [Mineralys Therapeutics, Inc. return on invested capital (ROIC)](https://funkfolio.com/stock/MLYS/roic)

[Mineralys Therapeutics, Inc. (MLYS) overview: price, valuation and scorecard](https://funkfolio.com/stock/MLYS)

### Mineralys Therapeutics, Inc. return on equity (ROE): questions and answers

**What is Mineralys Therapeutics, Inc.'s return on equity?**

Mineralys Therapeutics, Inc. (MLYS) earned a return on equity of -23.9% in fiscal 2025 (the year ended December 31, 2025). That is 69.1 percentage points higher than the -93.0% of fiscal 2024.

**What are the highest and lowest return on equity figures on record for Mineralys Therapeutics, Inc.?**

Across the 3 fiscal years on record (2023–2025), the highest was -23.9% in fiscal 2025 and the lowest -93.0% in fiscal 2024.

**How is Mineralys Therapeutics, Inc.'s return on equity calculated?**

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

### Learn: return on equity (ROE)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Return on invested capital (ROIC) vs ROE and ROA](https://funkfolio.com/learn/stocks/return-on-invested-capital)

  Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Mineralys Therapeutics, Inc. (MLYS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/MLYS/roe

Underlying data: Yahoo Finance.
